Compare Organon & Co. Common Stock (OGN) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Schwab US Dividend Equity ETF — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Schwab US Dividend Equity ETF trades at $33.99 (market cap $111.61B). The key difference: Schwab US Dividend Equity ETF is far larger — about 30.8× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Schwab US Dividend Equity ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Schwab US Dividend Equity ETF for 64 Days on average.
| OGN | SCHD | |
|---|---|---|
Market Cap | $3.62B | $111.61B |
Volume | 2,892,999 | 22,238,193 |
Sector | Health | Broad Market / Factor |
52-Week High | $13.81 | $35.21 |
52-Week Low | $5.70 | $26.44 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
SCHD trades at $33.37, up 0.33% with a bullish technical signal from moving averages. Recent news highlights SCHD outperforming the S&P 500 in 2026 and growing its dividend. The ETF's defensive dividend strategy faces scrutiny after missing gains from stocks like Broadcom due to its selection rules.
The outlook remains positive for income investors seeking quality dividend growth with lower risk through diversification. Key risks include interest rate sensitivity and the opportunity cost of excluded high-growth stocks. Current technical strength supports near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
